CD4 and neoplasm: While class I HER2-DC1 enhanced only CD8+ T cell infiltration but not CD4+ T cells, class II HER2-DC1 vaccination induced both CD4 and CD8+ T cell infiltration, suggesting that vaccination with class II HER2-DC1 may be sufficient in generating anti-tumor immunity and HER2-specific immune responses.